Fri, Aug 1, 2014, 9:20 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Aeterna Zentaris Inc. Message Board

  • taexpert928 taexpert928 Feb 15, 2013 1:40 PM Flag

    Overall survival of 30.4 months for bortezomib relapsed patients in Phase 2 of AEZS-108

    At the 2011 ASH meeting, Dr. Paul Richardson, MD, Associate Professor in the department of medicine at Harvard Medical School, presented the final data for one of these Phase 1/2 trials which he conducted in 73
    Very good results in phase 2 should bring very good results of phase 3 on Monday
    patients. Results showed a median overall survival of 25 months for all evaluable patients, including 30.4 months for 20 bortezomib relapsed patients and 22.5 months for 53 bortezomib refractory patients.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.14-0.04(-3.39%)Aug 1 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.